Priyanka Chablani, MD, MS
@PriyankaChabla1
Followers
81
Following
86
Media
0
Statuses
65
Genitourinary Medical Oncologist and Assistant Professor at University of Pittsburgh Medical Center (UPMC) and Pittsburgh VA
Pittsburgh
Joined February 2021
RT @DrYukselUrun: #FDA approves darolutamide for metastatic castration-sensitive #prostatecancer.@US_FDA @ASCO @APCCC_Lugano @OncoAlert #AS….
0
33
0
RT @neerajaiims: Breaking news @ASCO #ASCO25 👉 1st biomarker selected, positive ph3 trial in mHSPC #ProstateCancer 👉Abiraterone+ niraparib/….
0
50
0
RT @yekeduz_emre: LITESPARK-004 (5-yr f/u):.Belzutifan in VHL disease–associated tumors (n=61).🎯 ORR:.• RCC: 70%.• CNS HB: 50%.• pNETs: 90%….
0
6
0
RT @zklaassen_md: TiP: TRIPLE-SWITCH -- Ph III RCT for adding Doce to ARPIs in mCSPC and subopt PSA resp @urotoday #ASCO25 . 🔷n=830.🔷Subopt….
0
18
0
RT @drenriquegrande: EV-P is the right treatment. It’s time to learn how to really use it. #JacquelineBrown said. Wonderful discussion of n….
0
27
0
RT @DrKarineTawagi: Excellent discussion on peri-op MIBC, gem/cis/durva SOC for cis-eligible, many ❓remain:. ➡️ IO w/ TMT? #BRIGHT study lo….
0
6
0
RT @DrChoueiri: 📢 #ASCO25 | Biomarkers in Kidney Cancer: Are We There Yet? | Review of RCC biomarker landscape: PD‑L1, TMB, ctDNA, gene exp….
0
15
0
RT @ziremozay: 🌟 Brilliant presentation by @montypal at #ASCO25! . Genomic analysis from IMmotion010👉 High KIM-1/Teff shows longer DFS with….
0
17
0
RT @tompowles1: The 5 yr follow up for adjuvant pembro in RCC (KN564): continued benefit- DFS (5yr 52% v61% - HR0.71) OS (5yr 82% vs 88% H….
0
48
0
RT @DanaFarberNews: Dana-Farber extends our support to Former President Joe Biden and his family following news of his diagnosis with aggre….
0
21
0
RT @DrKarineTawagi: GU abstracts for #ASCO25!. Schedule & looking forward to:. 🔵PARPI in mCSPC #AMPLITUDE.-HRRm analysis #TALAPRO2.-prognos….
0
40
0
RT @LouiseKostos: Proud to share that our collaborative review on Combination Therapies in Locally Advanced PC and mHSPC is now available i….
0
25
0
RT @zklaassen_md: Survey-based study of Rx sequencing after 1L EV + P in la/mUC @PriyankaChabla1 @urotoday #GU25 . 78/227 (34%) response r….
0
10
0
RT @GUOncologyNow: 🚨 Coming soon: @PGrivasMDPhD, @PriyankaChabla1, @arkhaki, and @DrKarineTawagi discuss Dr. Chablani's survey-based study….
0
2
0
RT @urotoday: Survey-based Study of Treatment Sequencing After 1st Line Enfortumab Vedotin + Pembrolizumab in the Evolving Landscape of Loc….
0
8
0
RT @dr_coops: Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you ca….
0
94
0
RT @TiansterZhang: Combo Abi-olaparib better than sequential for BRCA1/2/ATM mutated #prostatecancer. Glad to see #BRCAaway published! Cong….
0
9
0
RT @PTarantinoMD: HER2: a remarkable story of precision oncology. Check this wonderful Nature review on targeting HER2 beyond breast. 👉Im….
0
110
0
RT @tompowles1: More evidence that PD(L)1 re-challenge should be avoided in renal cancer. Tivozanib+ Nivo showed no ⬆️ in efficacy v.s Tiv….
prnewswire.com
/PRNewswire/ -- AVEO Oncology, an LG Chem company ("AVEO"), announced today that the TiNivo-2 Phase 3 clinical trial in patients with advanced metastatic renal...
0
39
0